Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.
about
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Synergistic and targeted thera ...... ine malignant glioma patients.
@en
Synergistic and targeted thera ...... ine malignant glioma patients.
@nl
type
label
Synergistic and targeted thera ...... ine malignant glioma patients.
@en
Synergistic and targeted thera ...... ine malignant glioma patients.
@nl
prefLabel
Synergistic and targeted thera ...... ine malignant glioma patients.
@en
Synergistic and targeted thera ...... ine malignant glioma patients.
@nl
P2093
P2860
P356
P1433
P1476
Synergistic and targeted thera ...... ine malignant glioma patients.
@en
P2093
Alexandra Borodovsky
Antonella Mangraviti
Avadhut D Joshi
Betty Tyler
Gregory J Riggins
Howard S Roth
Jayme S Looper
Lisa J Schlein
Michael Podell
Paul J Hergenrother
P2860
P304
80124-80138
P356
10.18632/ONCOTARGET.19085
P407
P577
2017-07-07T00:00:00Z